^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR expression + ALK positive

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    1956; 238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR and ALK Positive Non-small-cell Lung Cancer Treated in the Real-World. (PubMed, Clin Lung Cancer)
    Approximately 18% of patients with advanced EGFR and ALK positive NSCLC do not receive TKIs and have inferior survival. Further studies need to investigate barriers of access to TKIs in biomarker-selected patients.
    Clinical • Journal • Real-World Evidence
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • EGFR expression + ALK positive
    almost4years
    Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer. (PubMed, JCO Oncol Pract)
    Compared with Q1-3, Q4 patients had inferior OS (adjusted hazard ratio [HR], 1.85; [95% CI, 1.11 to 3.10], similar TKI DOT (adjusted HR, 1.06; 95% CI, 0.53 to 2.15), decreased TKI adherence (adjusted odds ratio [OR], 0.28; 95% CI, 0.10 to 0.76), and higher TKI discontinuation rate (adjusted OR, 8.75; 95% CI, 2.59 to 29.52). Among patients with advanced EGFR- and ALK-positive NSCLC, higher TKI OOP costs are associated with decreased TKI adherence, a higher likelihood of TKI discontinuation, and inferior survival.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • EGFR expression + ALK positive